Advertisement

Topics

EC grants new indication for Soliris to treat refractory generalized myasthenia gravis

05:16 EDT 22 Aug 2017 | Pharmaceutical Business Review

Alexion Pharmaceuticals announced that the European Commission (EC) approved the extension of the indication for Soliris (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive.

Original Article: EC grants new indication for Soliris to treat refractory generalized myasthenia gravis

NEXT ARTICLE

More From BioPortfolio on "EC grants new indication for Soliris to treat refractory generalized myasthenia gravis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...